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Edited by Horst FeldmannAbstract Twofold diﬀerences in gene expression levels can be
vital for an organism. This is beautifully illustrated by the
process of ‘dosage compensation’ in Drosophila, which doubles
transcription from the single male X chromosome to equal the
mRNA levels originating from the two X chromosomes in female
cells. Failure of the process leads to male-speciﬁc lethality. A
number of recent publications have furthered our understanding
of the ribonucleoprotein complex, which mediates dosage com-
pensation and how it targets the male X chromosome. Deci-
phering the principles of X chromosome recognition and the
nature of the chromatin conﬁguration, that allows ﬁne-tuning of
transcription, remain the most interesting challenges.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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RNA; Transcription1. Dosage compensation and epigenetic gene regulation
In diploid cells, proteins are commonly expressed from both
alleles and their expression levels are adjusted accordingly.
Exceptions from this rule are imprinted genes, which are not
considered here, and X chromosomal genes in species with
heteromorphic sex chromosomes, like humans and fruit ﬂies.
In these cases the female genotype features two X chromo-
somes, whereas male cells carry only one X chromosome in
addition to the gene-poor Y chromosome. Fine-tuning of
protein expression levels involves compensation of the diﬀerent
doses of X-linked genes in the two sexes. During evolution,
several parallel dosage compensation strategies have arisen [1].
Inactivation of one female X chromosome in humans leaves
both sexes with one active allele, which is regulated to meet the
needs of the cell. More complicated regulatory schemes are in
place in the worm, Caenorhabditis elegans, where both female
X chromosomes are dampened to half activity, and in fruit
ﬂies, where the single male X chromosome is activated two-
fold. The twofold adjustments in transcription implemented in
the latter two cases are vital: failure is lethal for male ﬂies and
worms. In all three systems mentioned, dosage compensation
involves changing the transcription rates of relevant genes* Corresponding author. Fax: +49-89-5996-425.
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doi:10.1016/j.febslet.2004.03.110through modulation of their chromatin organization. This is
most obvious in the human case, where one of the two female
X chromosomes is globally inactivated by conversion of the
chromatin into facultative heterochromatin [2,3].
The folding of the nucleosomal ﬁbre into higher-order
structures may lead to states that are either repressive or per-
missive for transcription. The precise nature of these conﬁgu-
rations is not known, let alone the speciﬁcs that allow ﬁne
tuning of transcription in a twofold range. However, it is clear
that chromatin folding correlates with patterns of post-trans-
lational histone modiﬁcations and corresponding non-histone
proteins involved in setting and interpreting these modiﬁcation
marks [4,5]. Site-speciﬁc, post-translational modiﬁcations of
the N-terminal domains of histones are hallmarks of chro-
matin conﬁgurations with functional consequences. Among
them, histone phosphorylation and acetylation are suited to
constitute quick, reversible switches between functional states,
whereas methylation appears to be most suited to implement a
lasting chromatin conﬁguration. The observation of a wealth
of diﬀerent modiﬁcations has led to the concept of a ‘histone
code’ according to which patterns of modiﬁcations determine
the functional state of chromatin [5].
Inactivation of one of the human X chromosomes involves
methylation of both histone and DNA components of chro-
matin [3]. By contrast, activation of the single male X chro-
mosome in Drosophila is at least in part due to acetylation of
histone H4 at lysine 16 (H4K16) [6,7]. The mechanistic rela-
tionship between certain modiﬁcations and functional states is
not known. Methylated histones can be bound by non-histone
proteins involved in chromatin organization, such as the het-
erochromatin protein 1 or the developmental repressor poly-
comb [8,9]. So far no ligand for acetylated H4K16 has been
identiﬁed. In any case it is assumed that modiﬁcation of hi-
stone N-terminal tails will aﬀect the tightness and type of
chromatin folding by modifying the tails’ molecular interac-
tions. Setting up a particular chromatin conﬁguration is a
multi-step process coordinated by complex assemblies of pro-
teins. Interestingly, in both human X inactivation and ﬂy X
activation, long non-coding RNAs are crucial for the process
[10,11]. ‘Coating’ of the chromatin with these regulatory
RNAs provides a visual impression of their involvement in
altering chromatin structure.
The rich phenomenology of dosage compensation in human
cells, worms and ﬂies provides excellent opportunities for ex-
ploring the intricacies of gene regulation through chromatin
organization. Mainly due to its potential for genetic analysis,
our understanding of the process in Drosophila is mostblished by Elsevier B.V. All rights reserved.
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progress in this area and summarize the state of knowledge in a
speculative model.2. The dosage compensation complex of Drosophila
Dosage compensation in Drosophila is mediated by a ribo-
nucleoprotein complex known as the dosage compensation
complex (DCC), which forms in male cells and coats most of
the X chromosome. Five protein components of the DCC are
generally known as the MSL (male-speciﬁc lethal) proteins:
MSL1, -2 and -3, MLE (maleless; a helicase) and MOF (males
absent on the ﬁrst; a histone acetyltransferase (HAT)) (Fig. 1).
Much of what is known about these proteins has been re-
viewed recently elsewhere [12]. A sixth protein member of the
DCC, the JIL1 histone H3 kinase, is also enriched on the X
chromosome and interacts with the MSL proteins [13,14]. No
MSL phenotype has yet been identiﬁed for JIL1 as it is es-
sential in other processes [15], but hypomorphic JIL1 alleles
produce a lower male to female ratio [14]. The example of JIL1
reminds us that factors which have additional, more general
functions, besides their roles in dosage compensation, will not
have been identiﬁed by screens for male-speciﬁc lethality. In
addition to the protein factors, two non-coding RNAs, roX1
and roX2 (RNA on the X) are essential, albeit redundant,
components of the DCC [10,16–18].
Targeting of the MOF HAT results in X-speciﬁc acetylation
of H4K16, which correlates with reduced chromosome com-
paction relative to the autosomes and the female X chromo-
somes [6,19]. H4K16 acetylation by MOF has been shown to
cause de-repression of chromatin transcription in vitro and in
vivo [7].3. Assembly of the DCC
In early development, the mechanism of sex determination
detects gender and directs the appropriate male or female de-Fig. 1. Assembly of the DCC. In males, expression of MSL2 mediates stable
their assembly into the DCC. The complex possesses helicase/ATPase (MLE
expressed and blocks MSL2 production. The resulting deﬁciency for MSL2
stability of MSL1, MSL3 and both roX RNAs (shown here by their transpare
in females, as both proteins are expressed.velopment pathways, including the appropriate expression of
the DCC in males. The master regulator of the sex determi-
nation pathway is sex lethal (SXL) (for review see [20]). Gen-
der determination by SXL involves a number of numerator
(X-linked) and denominator (autosomal) loci used to somehow
sense the X to autosome ratio [21]. SXL expression is thereby
activated and maintained by positive feedback in female cells,
triggering the female development pathway. SXL concomi-
tantly inhibits translation of the MSL2 mRNA by blocking its
interaction with the ribosome [22]. Suppression of MSL2
prevents DCC formation in females, as MSL1 and MSL3 re-
quire MSL2 protein for sustained expression [23,24] (see
Fig. 1). Initial doses of the other MSL proteins are maternally
provided [25], but MSL2 expression in male embryos at blas-
toderm is necessary and suﬃcient to trigger DCC formation.
Accordingly, ectopic expression of an MSL2 transgene in fe-
males is suﬃcient to induce complex formation on both female
X chromosomes, accompanied by a drastic reduction in female
viability [24]. Initial transcription of roX1 RNA is independent
of the MSLs and occurs also in females, although the RNA
soon requires MLE for stability [26]. roX2 expression is male-
speciﬁc and occurs slightly later in embryogenesis. However,
continued expression and stability of the roX RNAs depends
on the MSL proteins [26]. Complete DCC is ﬁrst observed
binding to the male X chromosome approximately 3 h after
egg laying, just prior to detection of the acetylation of H4
lysine 16 [26].
A number of biochemical studies have documented the
protein–protein interactions within the DCC. Brieﬂy, MSL1 is
able to interact with MSL2, MSL3 and MOF and hence co-
ordinate their assembly into a stable, soluble complex with
robust and speciﬁc HAT activity in the absence of RNA
[14,24,27,28]. A host of genetic studies imply an interdepen-
dence of the complex components for assembly which have
been used to suggest a pathway for the stepwise assembly of
the DCC (for review, see [29]). Accordingly, MSL1 and MSL2
are at the base of DCC assembly, since they are interdependent
for X chromosome binding and will do so in the absence of any
of the other sub-units in vivo [30]. However, the recent study of
Meller [26] highlighted the maternal provision of all MSLsexpression of the other protein and RNA sub-units, and coordinates
), HAT (MOF) and histone kinase (JIL1) activities. In females, SXL is
prevents DCC formation and results in lower expression and/or in-
ncy). In contrast, MLE and MOF may also have yet unidentiﬁed roles
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MSL2 may simply complete an already organized complex.
Of considerable interest are the interactions between roX
RNAs and the MSL proteins as well as the role of these RNAs
in DCC function. MLE, an RNA helicase, may act as an RNA
chaperone required to integrate roX RNA into the DCC.
Deletion of MLE limits the localization of both roX RNAs to
their sites of synthesis [31]. Besides MLE, DCC sub-units
MSL3 and MOF are also able to bind RNA. Their interaction
with the X chromosome is sensitive to RNA degradation in
isolated nuclei [6,32–35], suggesting that they contact roX
RNA in vivo. MSL3 requires MOF for X chromosome bind-
ing, and both MSL3 and MOF require MLE [36,37]. Inter-
action with RNA (and hence chromosomal association of the
RNA binding sub-units) may be a regulated event. Akhtar and
colleagues [35] found that MOF is capable of acetylating
MSL3 and that this acetylation led to a loss of MSL3’s RNA
binding and X chromosome association. Acetylation of MSL3
may therefore represent a regulatory modiﬁcation controlling
association with the X chromosome. MOF is also capable of
acetylating MSL1 and of self-acetylation [28,35], opening
further possible avenues for regulation.
A complex consisting of only DCC proteins (and no roX
RNA) is partially functional and is able to support survival if
MSL1 and MSL2 are overexpressed in ﬂies [34]. This indicates
that roX RNA function is more prominent at limiting physi-
ological MSL protein levels. Under normal conditions, incor-
poration of roX RNA is necessary for dosage compensation:
simultaneous deletion of roX1 and roX2 is lethal for males.Fig. 2. A hierarchy of binding sites for the DCC. All images are of polytene ch
male (A), the DCC binds to hundreds of sites on the X chromosome. In a m
about 60–70 sites. In the absence of MSL3 and/or MOF (C), a partial compl
the MSL1 and MSL2 minimal complex binds reproducibly to about half ofAlthough roX1 and roX2 show almost no sequence similarity
and are expressed at diﬀerent times during embryonic devel-
opment, they have redundant functions as either can be singly
deleted without loss of dosage compensation [18,26,31]. This
suggests that diﬀerent complexes can exist with either RNA,
but it is not clear if any complexes contain both RNAs.
Likewise, the stoichiometry of the MSL proteins in a func-
tional DCC is not known.4. DNA determinants of DCC association with the
X chromosome: entry sites
Mutations in any MSL protein sub-unit abolish coating of
the X chromosome by the DCC and dosage compensation.
However, mutations in MLE, MSL3 or MOF reveal a dras-
tically reduced, yet reproducible set of binding sites for partial
complexes on the X chromosome (Fig. 2). These are proposed
to be high aﬃnity entry sites, that may serve as nucleation
sites from which the complex can spread in cis to coat adjacent
regions of the chromosome [38–40]. Interestingly, two of these
entry sites are found within the roX1 and roX2 genes [31,38].
The discovery that the roX genes not only contained high af-
ﬁnity sites, but could also mediate ‘spreading’ of the DCC
from an autosomal transgene into ﬂanking chromatin
[31,38,41] led to the proposal of the two step model of DCC
recruitment. In this model, complexes ﬁrst assemble at one of
the 35–55 high aﬃnity ‘entry sites’, then ‘diﬀuse’ preferentially
in cis to coat the remainder of the X chromosome (spreading).romosomes stained for MSL1 in red and DNA in blue. In the wild-type
of1 mutant (B), the DCC is complete, but not functional and binds to
ex binds to about 55 of these sites. Finally, in the absence of MLE (D),
these sites and weakly to the rest.
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the DCC is targeted to the X chromosome, including the na-
ture of the entry sites, the role of the RNAs, as well as the
importance of tight regulation of DCC concentration (see
below). As more phenomena are being revealed, the simple
‘spreading model’ has to be revised [42].
Over 50 entry sites of varying intensities have been mapped
cytologically on polytene chromosomes [30,40]. This is illus-
trated in Fig. 2, which also summarizes the binding patterns
of partial and non-functional complexes in other mutant
backgrounds. A minimal complex consisting of only MSL1
and MSL2 can only bind reproducibly to about half of the
full set of sites, but when MLE is present, the aﬃnity for
most of the sites is increased. The same set of sites were also
observed to recruit complete DCC under conditions of low
complex concentrations achieved by reducing the amount of
MSL2 protein [40]. These genetic studies therefore suggest
that there exists a hierarchy of entry sites to which the DCC
has diﬀerent aﬃnities and that partial complexes may only be
able to bind to the highest aﬃnity sites (see Fig. 3). Curi-
ously, none of the DCC components have so far been shown
to have sequence-speciﬁc DNA binding activity.
The nature of the ‘entry sites’ is obviously of great interest.
They can be studied in vivo by integration of X-derived DNA
into autosomes [38]. If these sequences can attract the DCC to
the autosomal insertion, particularly in the absence of MSL3,
it contains an ‘entry site’. This assay, combined with chromatin
immuno-precipitation and DNase I hypersensitive site analy-
sis, allowed mapping of the roX1 and roX2 entry sites to 200–
300-bp fragments within the genes [31,38,39,43]. Comparison
of these sequences to the corresponding roX sequences from
other Drosophila species highlighted several short islands of
sequence conservation within a 110-bp region [43]. MutationFig. 3. Speculative model of how dosage compensation may be achieved. (A)
red). roX RNA is bound by MSL proteins as it is being transcribed from the
(light red) binding sites. (C) ‘Spreading’ of DCC involves association with unk
transcription), but is not propagated to inactive genes (red X). (D) The presen
production.of these sequences produced a variable reduction of DCC
binding in wild-type larvae. Although these analyses suggested
the ﬁrst sequence determinants of DCC binding in vivo, related
sequences from the X chromosome identiﬁed by homology in
silico did not recruit the DCC.
Characteristically, insertion of the roX entry sites on auto-
somes not only leads to recruitment of both complete and
partial DCCs, but in addition complexes can be seen to spread
out from the insertion site to label distinct interbands on
polytene chromosomes [31,38,41]. This ‘spreading’ into ﬂank-
ing chromatin is highly dependent on the levels of DCC
present and whether the endogenous roX1 and roX2 sites are
still present on the X chromosome ([34,41,43] and see below).
Interaction of the DCC with the roX entry sites is particularly
dependent on the presence of at least one roX RNA and MLE
[39,43] but independent of transcription through the site
[18,39].
Obviously, a more general ‘entry site’ deﬁnition requires
comparison of more than just two sequences. However, the
recent characterization of a third entry site, the ﬁrst outside of
a roX gene, did not allow further reﬁnement of the deﬁnition.
The ‘entry site’ within the 18D region of the X chromosome
does not share any obvious sequence similarity with the roX
sites and is also clearly diﬀerent in other respects [42]. Unlike
the roX entry sites, the 18D site does not seem to be tran-
scribed, nor does it require roX RNA to attract the DCC.
Binding of partial DCC complex in msl3 mutants could not be
demonstrated to a distinct sequence element of less than 510
bp unless multimerized. Finally, autosomal spreading from the
18D site was very limited.
The operational deﬁnition of ‘entry sites’ appears, therefore,
to subsume diverse sites of MSL binding, which may vary in
sequence, structure and in aﬃnity for complete or partial DCCInitially, only DC sub-complexes bind to high aﬃnity ‘entry’ sites (dark
X chromosome. (B) Complete DCC is able to interact with secondary
nown features of transcriptionally active chromatin (arrows symbolize
ce of the DCC at sites of active transcription leads to doubling of RNA
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quences are able to recruit the DCC when inserted into auto-
somes in wild-type males even if they do not contain a mapped
entry site [42]. This suggests that in addition to the entry sites,
which attract DCC sub-complexes (e.g., those lacking MSL3)
under ‘stringent’ conditions, other DNA sequence determi-
nants exist on the X chromosome, able to attract intact DCC.
The X chromosome, therefore, appears to contain a much
higher number of speciﬁc binding sites for targeting than
previously thought.5. The role of roX RNA in targeting
Available data are consistent with a role of roX RNA not for
assembly of the DCC, but for its proper binding to and dis-
tribution over the X chromosome. In the absence of roX RNA,
low levels of DCC can be found ectopically bound to auto-
somal sites indicating that the RNAs may assist in targeting
the DCC speciﬁcally to the X chromosome [31]. The RNA
seems to aﬀect targeting in multiple ways. First, proper tar-
geting and distribution of the DCC on the X chromosome
apparently requires well-balanced levels of protein and RNA
components. Unbalancing these levels by genetic trickery leads
to interesting phenomenology, which may suggest targeting
rules. For example, increasing the levels of MSL1 and MSL2
in ﬂies lacking one roX gene leads to accumulation of these
proteins around the remaining roX gene [34]. This has been
interpreted to mean that increased levels of protein compo-
nents lead to very eﬃcient, but premature, completion of
complex assembly at the site of roX transcription. The result is
that the DCC is less able to move to other sites. The underlying
assumption here is that sub-complexes may be more ‘mobile’
than complete complexes and, hence, that the chromosome
interactions are highly dynamic.
A number of studies indicate that the roX genes compete for
a limiting pool of MSL proteins, which they direct preferen-
tially to the chromosome in which they reside. These results
suggest that the transcription of the roX RNAs indeed has a
role in targeting or sequestering the complex to the X chro-
mosome, possibly by ensuring high local concentrations of the
complex [34,41,43]. On the other hand, roX RNAs can also
function in trans, suggesting that they also have a functional
role in the recognition of the X chromosome, conceivably
through interaction with the protein components. The lethality
caused by lack of both roX genes on the X chromosome can be
rescued by an ectopic autosomal roX transcript [18,44]. This
indicates that the roX RNA can explore the nucleoplasm in
search of high aﬃnity ligands and that X chromosomal tar-
geting determinants are suﬃciently strong to attract the com-
plete DCC, even without the concentration eﬀect of local
transcription. The entry sites found within the two roX genes
are also not strictly required for the initiation of faithful tar-
geting of the DCC, since roX1 or roX2 RNAs lacking their
entry sites can rescue a double roX mutant [43]. The functional
elements of roX RNA, which may correspond to binding sites
for MSL proteins and perhaps other, yet unknown factors, are
still mysterious. A recent detailed study indicated that roX1
RNA contains several redundant functional elements, al-
though the 30 600 bp appeared to be most important for pro-
cessing and localization [44]. roX1 may thus contain multiple
functional elements, which could either contribute to targetingof the complex or serve as a scaﬀold for the arrangement of
MSL proteins within the DCC, as has been suggested for the
Xist RNA involved in mammalian dosage compensation [11].6. ‘Spreading’ of the DCC over the X chromosome
In support of the two-step targeting and spreading model
[38], the ATPase and HAT activities of MLE and MOF, re-
spectively, are not required for initial entry site recognition but
are essential for spreading [45] (Fig. 2). The roX RNAs are also
required for spreading [18,41]. However, considering the
multitude of DCC binding sites with diﬀerent properties, the
model is clearly an over-simpliﬁcation. Accordingly, the model
has since been modiﬁed to incorporate a signiﬁcant amount of
spreading by soluble complex in trans [34,41].
Considering the two steps of the model, ‘recruitment’ to
entry sites and ‘spreading’ into neighbouring chromatin, in-
teresting analogies to the dosage compensation processes in
humans and C. elegans can be observed. The process of X
inactivation in humans is a multi-step process involving several
chromatin modiﬁcations. It is initiated by the stabilization of a
non-coding RNA, Xist, transcribed from a tightly regulated X
inactivation centre (Xic) on the chromosome to be inactivated
[2,11]. Through unknown principles, the Xist RNA is then
directed to selectively ‘coat’ the X chromosome to be inacti-
vated, which in turn leads to implementation of heterochro-
matin through successive histone deacetylation, histone
methylation, incorporation of histone variants, and, ﬁnally,
DNA methylation [2,11]. Most recently, evidence for a ‘two-
step’ model of dosage compensation involving the recruitment
of a DCC to deﬁned sites on the X chromosomes, followed by
‘spreading’ into the neighbouring chromatin, has also been
obtained in C. elegans [46].
But what does ‘spreading’ really mean? The term suggests a
continuous propagation from an initiation point (e.g., an entry
site) into the neighbouring chromatin, but does not indicate
what the ‘unit size’ of chromatin interaction might be. Con-
ceptually, DCCs could make contacts with each individual
nucleosome of the chromosome as they move along a nucle-
osomal array, or just with the outside of a 30-nm chromatin
ﬁbre. Alternatively, in a scenario of diﬀerent extremes, the
DCC may just concentrate in specialized locus control regions
dedicated to specifying the activity of a large chromosomal
domain [47]. Spreading of heterochromatin is a generally ac-
cepted phenomenon in position eﬀect variegation, where
propagation of constitutively heterochromatic regions (such as
pericentromeric and sub-telomeric regions) can be seen into
neighbouring euchromatin if heterochromatin proteins are
overexpressed [8]. Similarly, spreading of the DCC is facili-
tated when MSL1 and MSL2 are overexpressed, leading to
promiscuous binding to many autosomal sites including the
heterochromatin of the fourth chromosome and the chromo-
centre [40]. A careful regulation of MSL and roX RNA con-
centrations is therefore important to limit DCC activity to
appropriate targets [34,40,41].
However, if ‘spreading’ of the DCC involves a continuous
propagation of complexes, there must be principles that re-
strict this propagation in analogy to boundary elements, which
limit the action of heterochromatin components [40,45]. This is
because the binding pattern of the DCC in wild-type males is
quite discontinuous and includes many gaps [40]. These sites
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gene-poor polytene bands, blocks of inactive genes, or to areas
ﬁlled with genes whose activity is compensated by an alter-
native strategy (for example, by down-regulation in females by
SXL [24]). Spreading from autosomal roX inserts is similarly
discontinuous and may ‘jump’ over several hundreds of kilo-
bases [41]. This suggests that the process does not involve a
continuous wrapping of the chromatin ﬁbre, but rather that
the DCC travels in a saltatory fashion. The question, then,
becomes as to what the determinants of the distributed (non-
entry) binding sites might be. The observation that the DCC
was recruited to actively transcribed genes [48] may suggest
that some aspect of transcription, such as a speciﬁc chromatin
conﬁguration or even the polymerase machinery itself, could
be recognized. However, this type of targeting to active genes
would have to be discriminative as well, as there are several
transcriptionally active areas on the X chromosome which are
devoid of DCC (I.K.D., unpublished).
Several of the above-mentioned observations challenge the
previous assumption that DCC distribution may mainly be due
to regulated cis and/or trans spreading originating from just a
few entry sites. In addition, the fact that about half of the gaps
in DCC staining on the X chromosome reside immediately
adjacent to entry sites [40] suggests that bidirectional spreading
in cis from these sites does not occur, at least at the level of
resolution characteristic of polytene chromosome analysis.
Furthermore, part of the third chromosome transposed to the X
chromosome did not attract DCC binding despite being ﬂanked
by regions of bound complex and the presence of an entry site
nearby, arguing against indiscriminate spreading in cis and
trans [42].
Considering these ﬁndings, a revised model may be proposed
(Fig. 3).Accordingly, transcription ofMSL2and stabilizationof
MSL1 lead to formation of partialDCCs complexes able to bind
to high aﬃnity sites on the X chromosome (Fig. 3(a)). Tran-
scription of the roX RNAs from the X chromosome and their
incorporation into close-by complexes leads to formation of
complete complexes, with enhanced aﬃnity for high and mod-
erate aﬃnity sites, which they reach by diﬀusion (Fig. 3(b)). As
the complex levels rise, lower aﬃnity sites are increasingly rec-
ognized, which reinforces the accumulation of the complex
throughout the X chromosomal territory. Once a suﬃciently
high level of complex has been reached, the DCC is attracted
locally to active genes in order to compensate transcription
(Fig. 3(c) and (d)).According to thismodel, the closer a gene is to
high aﬃnity sites (in space, not necessarily on a linear chromatin
ﬁbre!) the more likely its encounter with DCCs would be. This
model explains variable- and concentration-dependent spread-
ing from roX genes on autosomes, as these could potentially
contain low aﬃnity sites for binding that are recognized at high
complex concentration. It also explains that overexpression of
MSL1 andMSL2 leads to increased autosomal binding, as once
complex levels are suﬃciently high, the DCC can spread outside
theX chromosomal territory and locatemoderate or low aﬃnity
sites on autosomes.7. More questions than answers
Unresolved questions revolve around the role of the critical
acetylation of H4K16 in the compensation process. In vitroand in vivo experiments show that this single modiﬁcation can
lead to de-repression of transcription on chromatin templates
[7]. Is the dosage compensation machinery then solely a
complex device to assure proper targeting of MOF activity?
Dosage compensation in ﬂies does not involve derepression of
a chromatin template, but a twofold enhancement of what-
ever transcriptional activity would be characteristic for a gi-
ven gene, which may require feed-back principles yet to be
uncovered. Other chromatin features yet to be described may
also contribute to proper gene regulation by the DCC. For
example, we currently know nothing of the role of JIL1 in
dosage compensation; since H3 phosphorylation at serine 10
is a hallmark of immediate-early gene activation, particularly
if combined with H3 acetylation [49] this modiﬁcation may
play a role as well. Currently, the best proposal of how the
altered chromatin conﬁguration might be translated into a
twofold enhancement of gene expression is that it aﬀects
transcription at the level of elongation [48]. Recently, with the
identiﬁcation of new factors dedicated to regulating RNA
polymerase elongation in the chromatin ﬁbre, the complexities
of this process have been further appreciated [50]. Inheritance
of gene expression patterns through epigenetic principles re-
quires that a stable chromatin conﬁguration is propagated
from one chromosome generation to the next, independent of
the cues that originally deﬁned the pattern. Whether this is
the case for dosage compensation in Drosophila can only be
evaluated once the principles are known by which the X
chromosomal domains are identiﬁed. Among the pertinent
questions to be answered is whether this identiﬁcation hap-
pens only once during early embryonic development (in which
case the maintenance of the pattern will rely on purely epi-
genetic principles), or after each round of DNA replication.
The MSL proteins remain associated with the male X chro-
mosome throughout the cell cycle ([51]; T. Straub, I.K.D. and
P.B.B, unpublished observations) and may therefore be di-
rectly involved in the deﬁnition of the hyperactive nuclear
domain. Repressive, heritable chromatin conﬁgurations com-
monly rely on stable methylation of DNA and histones,
which is reinforced by interacting proteins and tethering of
methylases. Certain methylation marks, such as methylation
of histone H3 lysine 4, are correlated with active chromatin
[52]. It will be interesting to ﬁnd out whether stable modiﬁ-
cations of this kind are involved in permanent marking of the
hyperactive X chromosome, or whether H4K16 acetylation
(perhaps in combination with histone H3 phosphorylation)
may ﬁll the role of epigenetic mark for the activation needed
in Drosophila dosage compensation. Alternatively, perhaps
the DCC requires the ﬂexibility to rapidly compensate acti-
vated X-linked genes, yet also to be rapidly removed when
these genes are turned oﬀ again, as part of a developmental
program. Relatively stable histone methylation would there-
fore be inappropriate and a modiﬁcation with a rapid turn-
over desirable.
The concerted modulation of transcriptional activity of large
chromosomal domains is a requirement for dosage compen-
sation in species as diﬀerent as ﬂies, worms and humans. Be-
cause several key RNA and protein components involved in
dosage compensation in Drosophila are known, the system
appears well suited to unravel basic principles that assure
discrimination between the chromosomes and the assembly
and inheritance of chromatin conﬁgurations that permit the
ﬁne-tuning of transcription within a twofold range. It is likely
14 G.D. Gilﬁllan et al. / FEBS Letters 567 (2004) 8–14that these basic principles will turn into recurring themes once
we know more about dosage compensation in diverse species.
Acknowledgements: Research on dosage compensation in the labora-
tory of the authors is supported by the Deutsche Forschungsgeme-
inschaft through ‘Transregio 5’ and the BMBF Verbundprojekt
PTJ-Bio/0313030B. We thank M. Chioda and V. Maier for critical
reading of the manuscript.References
[1] Pannuti, A. and Lucchesi, J.C. (2000) Curr. Opin. Genet. Dev. 10,
644–650.
[2] Cohen, D.E. and Lee, J.T. (2002) Curr. Opin. Genet. Dev. 12,
219–224.
[3] Avner, P. and Heard, E. (2001) Nat. Rev. Genet. 2, 59–67.
[4] Jenuwein, T. and Allis, C.D. (2001) Science 293, 1074–1080.
[5] Fischle, W., Wang, Y. and Allis, C.D. (2003) Curr. Opin. Cell
Biol. 15, 172–183.
[6] Smith, E.R., Pannuti, A., Gu, W., Steurnagel, A., Cook, R.G.,
Allis, C.D. and Lucchesi, J.C. (2000) Mol. Cell. Biol. 20, 312–318.
[7] Akhtar, A. and Becker, P.B. (2000) Mol. Cell 5, 367–375.
[8] Richards, E.J. and Elgin, S.C. (2002) Cell, 489–500.
[9] Orlando, V. (2003) Cell 112, 599–606.
[10] Kelley, R.L. and Kuroda, M.I. (2000) Cell 103, 9–12.
[11] Wutz, A. (2003) Bioessays 25, 434–442.
[12] Akhtar, A. (2003) Curr. Opin. Genet. Dev. 13, 161–169.
[13] Jin, Y., Wang, Y., Johansen, J. and Johansen, K.M. (2000) J. Cell
Biol. 149, 1005–1010.
[14] Wang, Y., Zhang, W., Jin, Y.H., Johansen, J. and Johansen, K.M.
(2001) Cell 105, 433–443.
[15] Zhang, W., Jin, Y., Ji, Y., Girton, J., Johansen, J. and Johansen,
K.M. (2003) Genetics 165, 1341–1354.
[16] Meller, V.H., Wu, K.H., Roman, G., Kuroda, M.I. and Davis,
R.L. (1997) Cell 88, 445–457.
[17] Amrein, H. and Axel, R. (1997) Cell 88, 459–469.
[18] Meller, V.H. and Rattner, B.P. (2002) EMBO J. 21, 1084–1091.
[19] Bone, J.R., Lavender, J., Richman, R., Palmer, M.J., Turner,
B.M. and Kuroda, M.I. (1994) Genes Dev. 8, 96–104.
[20] Penalva, L.O. and Sanchez, L. (2003) Microbiol. Mol. Biol. Rev.
67, 343–359, table of contents.
[21] Cline, T.W. and Meyer, B.J. (1996) Annu. Rev. Genet. 30, 637–
702.
[22] Gebauer, F., Grskovic, M. and Hentze, M.W. (2003) Mol. Cell 11,
1397–1404.
[23] Palmer, M.J., Richman, R., Richter, L. and Kuroda, M.I. (1994)
Genes Dev. 8, 698–706.
[24] Kelley, R.L., Solovyeva, I., Lyman, L.M., Richman, R., Solovyev,
V. and Kuroda, M.I. (1995) Cell 81, 867–877.
[25] Rastelli, L., Richman, R. and Kuroda, M.I. (1995) Mech. Dev. 53,
223–233.
[26] Meller, V.H. (2003) Mech. Dev. 120, 759–767.[27] Scott, M.J., Pan, L.L., Cleland, S.B., Knox, A.L. and Heinrich, J.
(2000) EMBO J. 19, 144–155.
[28] Morales, V., Straub, T., Neumann, M., Mengus, G., Akhtar, A.
and Becker, P.B. (2004) EMBO J., in press.
[29] Amrein, H. (2000) Genome Biol. 1, Reviews 1030.
[30] Lyman, L.M., Copps, K., Rastelli, L., Kelley, R.L. and Kuroda,
M.I. (1997) Genetics 147, 1743–1753.
[31] Meller, V.H., Gordadze, P.R., Park, Y., Chu, X., Stuckenholz, C.,
Kelley, R.L. and Kuroda, M.I. (2000) Curr. Biol. 10, 136–143.
[32] Richter, L., Bone, J.R. and Kuroda, M.I. (1996) Genes Cells 1,
325–336.
[33] Akhtar, A., Zink, D. and Becker, P.B. (2000) Nature 407, 405–
409.
[34] Oh, H., Park, Y. and Kuroda, M.I. (2003) Genes Dev. 17, 1334–
1339.
[35] Buscaino, A., Kocher, T., Kind, J.H., Holz, H., Taipale, M.,
Wagner, K., Wilm, M. and Akhtar, A. (2003) Mol. Cell 11, 1265–
1277.
[36] Gorman, M., Franke, A. and Baker, B.S. (1995) Development
121, 463–475.
[37] Gu, W., Szauter, P. and Lucchesi, J.C. (1998) Dev. Genet. 22, 56–
64.
[38] Kelley, R.L., Meller, V.H., Gordadze, P.R., Roman, G., Davis,
R.L. and Kuroda, M.I. (1999) Cell 98, 513–522.
[39] Kageyama, Y., Mengus, G., Gilﬁllan, G., Kennedy, H.G.,
Stuckenholz, C., Kelley, R.L., Becker, P.B. and Kuroda, M.I.
(2001) EMBO J. 20, 2236–2245.
[40] Demakova, O.V., Kotlikova, I.V., Gordadze, P.R., Alekseyenko,
A.A., Kuroda, M.I. and Zhimulev, I.F. (2003) Chromosoma 112,
103–115.
[41] Park, Y., Kelley, R.L., Oh, H., Kuroda, M.I. and Meller, V.H.
(2002) Science 298, 1620–1623.
[42] Oh, H., Bone J.R. and Kuroda, M.I. (2004). Curr. Biol., 14, 481–
487.
[43] Park, Y., Mengus, G., Bai, X., Kageyama, Y., Meller, V.H.,
Becker, P.B. and Kuroda, M.I. (2003) Mol. Cell 11,
977–986.
[44] Stuckenholz, C., Meller, V.H. and Kuroda, M.I. (2003) Genetics
164, 1003–1014.
[45] Gu, W., Wei, X., Pannuti, A. and Lucchesi, J.C. (2000) EMBO J.
19, 5202–5211.
[46] Csankovszki, G., McDonel, P. and Meyer, B.J. (2004) Science
303, 1182–1185.
[47] Bulger, M., Sawado, T., Schubeler, D. and Groudine, M. (2002)
Curr. Opin. Genet. Dev. 12, 170–177.
[48] Sass, G.L., Pannuti, A. and Lucchesi, J.C. (2003) Proc. Natl.
Acad. Sci. USA 100, 8287–8291.
[49] Thomson, S., Clayton, A.L. and Mahadevan, L.C. (2001) Mol.
Cell 8, 1231–1241.
[50] Svejstrup, J.Q. (2002) Curr. Opin. Genet. Dev. 12, 156–161.
[51] Lavender, J.S., Birley, A.J., Palmer, M.J., Kuroda, M.I. and
Turner, B.M. (1994) Chromosome Res. 2, 398–404.
[52] Kouzarides, T. (2002) Curr. Opin. Genet. Dev. 12,
198–209.
